Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy

Crizotinib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity against mesenchymal-epithelial transition factor (MET) and anaplastic lymphoma kinase (ALK). However, the concomitant oncogenic drivers may affect the sensitivity of crizotinib. Herein, we present a 69-year-old never-smoker...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Hematol Oncol
Auteurs principaux: Gu, Fei-fei, Zhang, Yong, Liu, Yang-yang, Hong, Xiao-hua, Liang, Jin-yan, Tong, Fan, Yang, Jing-song, Liu, Li
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2016
Sujets:
Letter to the Editor
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4974806/
https://ncbi.nlm.nih.gov/pubmed/27496196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0296-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires